ENHANCING PRODIGIOSIN EFFICACY IN BREAST CANCER TREATMENT THROUGH EXERCISE: INVESTIGATING THE INTERPLAY BETWEEN PHYSICAL ACTIVITY AND MEDICATION RESPONSE

Abstract

Objective: This study investigates the impact of prodigiosin, a potent bacterial metabolite, on breast cancer cell behavior, specifically focusing on proliferation, migration, and spheroid formation. Additionally, we consider how physical activity might enhance these effects, given the known benefits of exercise on medication efficacy and cancer prognosis. Methods: Various concentrations of prodigiosin were administered to the normal human breast epithelial cell line MCF-10A and the human breast cancer cell line MCF-7 during logarithmic growth phases. The influence of prodigiosin on cellular proliferation was quantified using the MTS assay, migration through a wound-healing assay, and spheroid formation via a three-dimensional (3D) culture assay. Results: The study determined the half maximal inhibitory concentration (IC50) of prodigiosin for MCF-7 to be 140.8μM and for MCF-10A to be 231.4μM after 48 hours. Notably, prodigiosin significantly reduced proliferation and migration in MCF-7 cells more effectively than in MCF-10A, with a marked dose-response relationship (P<0.001). The compound also notably decreased the efficiency of spheroid formation in MCF-7 cells across multiple time points (48h, 72h, 96h). Conclusion: Prodigiosin exhibits substantial anti-tumor properties against breast cancer, significantly inhibiting key aspects of tumor cell dynamics. This research underscores the need for further studies to explore how integrating exercise with prodigiosin treatment could potentially amplify these anti-cancer effects, offering promising implications for enhancing treatment protocols in breast cancer patients through lifestyle modifications alongside pharmacological approaches.